CA2580306A1 - Techniques de detection de cancer ovarien - Google Patents
Techniques de detection de cancer ovarien Download PDFInfo
- Publication number
- CA2580306A1 CA2580306A1 CA002580306A CA2580306A CA2580306A1 CA 2580306 A1 CA2580306 A1 CA 2580306A1 CA 002580306 A CA002580306 A CA 002580306A CA 2580306 A CA2580306 A CA 2580306A CA 2580306 A1 CA2580306 A1 CA 2580306A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- cancer
- hypermethylation
- acid molecules
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010061535 Ovarian neoplasm Diseases 0.000 title claims abstract description 60
- 206010033128 Ovarian cancer Diseases 0.000 title claims abstract description 49
- 238000001514 detection method Methods 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title claims abstract description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 97
- 230000006607 hypermethylation Effects 0.000 claims description 69
- 210000002966 serum Anatomy 0.000 claims description 67
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 210000003567 ascitic fluid Anatomy 0.000 claims description 50
- 150000007523 nucleic acids Chemical class 0.000 claims description 40
- 238000007855 methylation-specific PCR Methods 0.000 claims description 38
- 102000039446 nucleic acids Human genes 0.000 claims description 38
- 108020004707 nucleic acids Proteins 0.000 claims description 38
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 claims description 34
- 108700020463 BRCA1 Proteins 0.000 claims description 28
- 102000036365 BRCA1 Human genes 0.000 claims description 28
- 101150072950 BRCA1 gene Proteins 0.000 claims description 28
- 230000011987 methylation Effects 0.000 claims description 26
- 238000007069 methylation reaction Methods 0.000 claims description 26
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 24
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 24
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 23
- 108010031042 Death-Associated Protein Kinases Proteins 0.000 claims description 16
- 102000005721 Death-Associated Protein Kinases Human genes 0.000 claims description 15
- 108010079351 Tumor Suppressor Protein p14ARF Proteins 0.000 claims description 13
- 239000012472 biological sample Substances 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 8
- 210000002381 plasma Anatomy 0.000 claims description 7
- 239000013641 positive control Substances 0.000 claims description 7
- 239000013642 negative control Substances 0.000 claims description 5
- 238000003752 polymerase chain reaction Methods 0.000 claims description 5
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- -1 p1.1ARF Proteins 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 2
- 238000003936 denaturing gel electrophoresis Methods 0.000 claims description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims 4
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims 4
- 108020004414 DNA Proteins 0.000 description 104
- 201000011510 cancer Diseases 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 23
- 201000010099 disease Diseases 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 230000002611 ovarian Effects 0.000 description 16
- 238000009396 hybridization Methods 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 12
- 230000001613 neoplastic effect Effects 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 10
- 108700028369 Alleles Proteins 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 239000000499 gel Substances 0.000 description 8
- 102100038587 Death-associated protein kinase 1 Human genes 0.000 description 7
- 101000956145 Homo sapiens Death-associated protein kinase 1 Proteins 0.000 description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 230000001594 aberrant effect Effects 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 208000005623 Carcinogenesis Diseases 0.000 description 4
- 108091029523 CpG island Proteins 0.000 description 4
- 206010011732 Cyst Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 230000036952 cancer formation Effects 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 208000031513 cyst Diseases 0.000 description 4
- 230000002380 cytological effect Effects 0.000 description 4
- 230000004076 epigenetic alteration Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000004077 genetic alteration Effects 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 208000025661 ovarian cyst Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000972773 Aulopiformes Species 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 238000000729 Fisher's exact test Methods 0.000 description 3
- 102100037948 GTP-binding protein Di-Ras3 Human genes 0.000 description 3
- 101000951235 Homo sapiens GTP-binding protein Di-Ras3 Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 108010079846 endometriosis protein II Proteins 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000005170 neoplastic cell Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091029430 CpG site Proteins 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 108091092878 Microsatellite Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 231100000118 genetic alteration Toxicity 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 208000015124 ovarian disease Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 208000026087 primary peritoneal tumor Diseases 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108700001666 APC Genes Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- 206010061803 Cyst rupture Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101710180995 Endonuclease 1 Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 230000010558 Gene Alterations Effects 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102100032530 Glypican-3 Human genes 0.000 description 1
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 1
- 208000033640 Hereditary breast cancer Diseases 0.000 description 1
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 201000005027 Lynch syndrome Diseases 0.000 description 1
- 101710167887 Major outer membrane protein P.IA Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 206010054827 Peritoneal lesion Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091027568 Single-stranded nucleotide Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 208000012172 borderline epithelial tumor of ovary Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000009799 cystectomy Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000025581 hereditary breast carcinoma Diseases 0.000 description 1
- 238000013090 high-throughput technology Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 230000033607 mismatch repair Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 208000012988 ovarian serous adenocarcinoma Diseases 0.000 description 1
- 201000005163 papillary serous adenocarcinoma Diseases 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2523/00—Reactions characterised by treatment of reaction samples
- C12Q2523/10—Characterised by chemical treatment
- C12Q2523/125—Bisulfite(s)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61004104P | 2004-09-15 | 2004-09-15 | |
| US60/610,041 | 2004-09-15 | ||
| PCT/US2005/032600 WO2006031831A2 (fr) | 2004-09-15 | 2005-09-14 | Techniques de detection de cancer ovarien |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2580306A1 true CA2580306A1 (fr) | 2006-03-23 |
Family
ID=36060651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002580306A Abandoned CA2580306A1 (fr) | 2004-09-15 | 2005-09-14 | Techniques de detection de cancer ovarien |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20080032292A1 (fr) |
| EP (1) | EP1794325A4 (fr) |
| CA (1) | CA2580306A1 (fr) |
| WO (1) | WO2006031831A2 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2193210B1 (fr) * | 2007-09-17 | 2014-11-12 | Koninklijke Philips N.V. | Procédé d'analyse des troubles liés au cancer de l'ovaire |
| EP2401408A4 (fr) | 2009-02-27 | 2012-06-13 | Univ Johns Hopkins | Méthylome du cancer des ovaires |
| WO2013096661A1 (fr) * | 2011-12-22 | 2013-06-27 | Illumina, Inc. | Biomarqueurs de méthylation utilisés pour le cancer de l'ovaire |
| KR102436737B1 (ko) * | 2020-05-12 | 2022-08-26 | 가톨릭대학교 산학협력단 | Brca1 유전자 메틸화를 이용한 난소암 발병 위험도 예측 방법 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5786146A (en) * | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| CA2478592A1 (fr) * | 2002-03-07 | 2003-09-18 | The Johns Hopkins University School Of Medicine | Depistage genomique pour genes lies au cancer rendus epigenetiquement silencieux |
-
2005
- 2005-09-14 US US11/575,249 patent/US20080032292A1/en not_active Abandoned
- 2005-09-14 WO PCT/US2005/032600 patent/WO2006031831A2/fr active Application Filing
- 2005-09-14 EP EP05814891A patent/EP1794325A4/fr not_active Withdrawn
- 2005-09-14 CA CA002580306A patent/CA2580306A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006031831A3 (fr) | 2006-06-29 |
| WO2006031831B1 (fr) | 2006-08-24 |
| WO2006031831A2 (fr) | 2006-03-23 |
| US20080032292A1 (en) | 2008-02-07 |
| EP1794325A4 (fr) | 2008-11-05 |
| EP1794325A2 (fr) | 2007-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| De Caceres et al. | Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients | |
| Hoque et al. | Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer | |
| US10113202B2 (en) | Method for determining the methylation status of the promoter region of the TWIST1 gene in genomic DNA from bladder cells | |
| Harden et al. | Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients | |
| Nakamura et al. | RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors | |
| JP4727149B2 (ja) | 体液中の遊離浮遊ｄｎａについて組織特異性を決定するための方法および装置 | |
| Katsaros et al. | Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer | |
| WO2009108917A2 (fr) | Marqueurs pour la détection améliorée du cancer du sein | |
| WO2021004215A1 (fr) | Réactif de détection combiné multigénique | |
| CN110964809B (zh) | Hoxa7甲基化检测试剂 | |
| CN114729399A (zh) | 检测卵巢癌 | |
| Lin et al. | Molecular profile and copy number analysis of sporadic colorectal cancer in Taiwan | |
| JP2022552400A (ja) | 特定の遺伝子のｃｐｇメチル化変化を利用した肝癌診断用組成物およびその使用 | |
| WO2009153667A2 (fr) | Procédé pour la détection du cancer des ovaires | |
| Xiong et al. | Mismatch repair deficiency and CpG island hypermethylation in sporadic colon adenocarcinomas | |
| US8609343B2 (en) | Detection of bladder cancer | |
| Collins et al. | Methylation of death-associated protein kinase in ovarian carcinomas | |
| Daniūnaitė et al. | Epigenomic technologies for deciphering circulating tumor DNA | |
| KR102472257B1 (ko) | LINC01798 유전자의 CpG 메틸화 변화를 이용한 대장암, 직장암 또는 대장 선종 진단용 조성물 및 이의 용도 | |
| Chang et al. | Detection of allelic imbalance in ascitic supernatant by digital single nucleotide polymorphism analysis | |
| US20080032292A1 (en) | Methods for the Detection of Ovarian Cancer | |
| US20230175070A1 (en) | Tumor detection reagent and kit | |
| Tzao et al. | 5′ CpG island hypermethylation and aberrant transcript splicing both contribute to the inactivation of the FHIT gene in resected non-small cell lung cancer | |
| TWI716883B (zh) | 腫瘤標誌物、甲基化檢測試劑、試劑盒及其應用 | |
| CA2599055C (fr) | Compositions de depistage de neoplasie et procedes d'utilisation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |